Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.58 |
| ▸ | MAPT | P10636 | 11/20 | 0.58 |
| ▸ | NPC1 | O15118 | 10/20 | 0.58 |
| ▸ | RAB9A | P51151 | 10/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.58 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349862 | 0.87 | CYP1A2 (0.58) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 | |
| SCHEMBL13225540 | 0.86 | CYP2C9 (0.47) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 | |
| SCHEMBL10312511 | 0.85 | CYP2C9 (0.53) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 | |
| SCHEMBL4548372 | 0.84 | CYP2C9 (0.68) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 | |
| SCHEMBL14349859 | 0.82 | HCAR2 (0.79) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 | |
| SCHEMBL14349861 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 | |
| SCHEMBL11903011 | 0.80 | SMN1; SMN2 (0.72) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 | |
| SCHEMBL13659249 | 0.78 | CYP1A2 (1.00) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 | |
| SCHEMBL14349878 | 0.78 | HCAR2 (0.52) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 | |
| SCHEMBL4548381 | 0.77 | NPC1 (0.44) | CYP1A2CYP2D6SMN1; SMN2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2008051403-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | CYP1A2 586/4885CYP2D6 1187/4885SMN1; SMN2 4003/4885 |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | CYP1A2 672/4885CYP2D6 1270/4885SMN1; SMN2 3956/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | CYP1A2 475/4885CYP2D6 1088/4885SMN1; SMN2 2600/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | CYP1A2 623/4885CYP2D6 1239/4885SMN1; SMN2 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.